aripiprazole vs ziprasidone

This entry refers to the direct comparison of two atypical (second-generation) antipsychotic drugs, aripiprazole and ziprasidone. Both are used primarily for the treatment of schizophrenia and bipolar disorder, with additional indications such as irritability associated with autistic disorder (aripiprazole), Tourette's disorder (aripiprazole), schizoaffective disorder, obsessive-compulsive disorder, and others. Aripiprazole acts mainly as a partial agonist at dopamine D2 receptors and serotonin 5-HT1A receptors, while antagonizing 5-HT2A receptors. Ziprasidone is an antagonist at dopamine D2 and serotonin 5-HT2A receptors, with additional activity at other serotonergic sites. Both drugs have demonstrated clinical efficacy in treating schizophrenia and are associated with a lower incidence of certain side effects like hyperprolactinemia compared to some other antipsychotics; however, their metabolic side effect profiles differ somewhat. Studies suggest minimal differences in overall efficacy but notable differences in tolerability profiles[1][2][3][9].

Brand names

AbilifyGeodon

Other names

aripiprazole vs. ziprasidone-Northwestern University-insulin resistance syndrome-schizophrenia-schizoaffective disorder-bipolar disorder